C Lewis

Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Amr E. Abbas, Fatima H. Abbas, Kaja Abbas et autres

BACKGROUND: Sotrovimab is a neutralising monoclonal antibody targeting the SARS-CoV-2 spike protein. We aimed to evaluate the efficacy and safety of sotrovimab in the RECOVERY trial, an investigator-initiated, individually randomised, controlled, open-label, adaptive platform trial testing treatments for patients admitted to hospital …

Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Amr E. Abbas, Fatima H. Abbas, Jonathan Raihan Abbas et autres

BACKGROUND: Molnupiravir and nirmatrelvir-ritonavir are oral antivirals that have shown efficacy in preventing disease progression in outpatients with COVID-19. We aimed to evaluate these treatments for patients hospitalised with COVID-19 pneumonia, for whom data on these antivirals are scarce. METHODS: The RECOVERY …

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial

Saul N. Faust, Richard Haynes, Christine Elizabeth Jones, Natalie Staplin et autres

BACKGROUND: Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS), also known as multisystem inflammatory syndrome in children (MIS-C) emerged in April, 2020. The paediatric comparisons within the RECOVERY trial aimed to assess the effect of intravenous immunoglobulin or corticosteroids compared with …

us, de, gb (code pays fourni par la source)

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Amr E. Abbas, Fatima H. Abbas, Jonathan Raihan Abbas et autres

BACKGROUND: Empagliflozin has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory, metabolic, and haemodynamic effects. The RECOVERY trial aimed to assess its safety and efficacy in patients admitted to hospital with COVID-19. METHODS: In the randomised, controlled, …

Rapid Implementation of Remote Online Patient Portal Activation in a Children's Hospital during the COVID-19 Pandemic

Kim Tai Vuong, Tiranun Rungvivatjarus, Isabel Pardo García, C Lewis et autres

Abstract Background Patient portal access allows more patient engagement, yet portal usage is not universal. Telemedicine visits became critical when the coronavirus disease 2019 (COVID-19) pandemic limited in-office visits. Given physical distancing requirements and telemedicine platform integrated into the patient portal, our …

us (code pays fourni par la source)

Managing central venous access during a health care crisis

Tristen T. Chun, Dejah R. Judelson, David Andrew Rigberg, Peter F. Lawrence et autres

us, gr, de, it, kr, sg, fr, ca, lk, mx, nz, ch, in (code pays fourni par la source)

From the editor

C Lewis